[go: up one dir, main page]

PE20080701A1 - Derivados de 3,4-dihidro-2h-benzo[1,4]oxazina y tiazina como inhibidores de cetp - Google Patents

Derivados de 3,4-dihidro-2h-benzo[1,4]oxazina y tiazina como inhibidores de cetp

Info

Publication number
PE20080701A1
PE20080701A1 PE2007000570A PE2007000570A PE20080701A1 PE 20080701 A1 PE20080701 A1 PE 20080701A1 PE 2007000570 A PE2007000570 A PE 2007000570A PE 2007000570 A PE2007000570 A PE 2007000570A PE 20080701 A1 PE20080701 A1 PE 20080701A1
Authority
PE
Peru
Prior art keywords
dihydro
phenyl
benzo
alkyl
thiazine
Prior art date
Application number
PE2007000570A
Other languages
English (en)
Inventor
Gee-Hong Kuo
Aihua Wang
Thomas Rano
Catherine Prouty
Keith T Demarest
Patricia Pelton
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38694691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20080701A1 publication Critical patent/PE20080701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 3,4-DIHIDRO-2H-BENZO[1,4]OXAZINA Y TIAZINA DE FORMULA (I), EN DONDE L ES ENLACE COVALENTE U O; X ES O U S; Q ES ARILO(C6-C10) O HETEROARILO DE 5 A 6 MIEMBROS; n Y m SON DE 0 a 3; R1 ES ALQUILO(C1-C10), ALQUENILO(C2-C10), ENTRE OTROS O ES FENILO SUSTITUIDO OPCIONALMENTE; R2 ES HALO, HIDROXI, CN, ALQUILO O ALCOXI(C1-C4) HALOGENADO, ENTRE OTROS; R3 ES ALQUILO(C1-C4), ALQUENILO(C2-C4), ENTRE OTROS; R4 ES ALQUILO(C1-C10) SUSTITUIDO OPCIONALMENTE CON 1 A 3 MIEMBROS DE HALO, OXO, HIDROXI, ENTRE OTROS. SON SELECCIONADOS: 1,1,1-TRIFLUORO-3-[3-[3-(1,1,2,2-TETRAFLUORO-ETOXI)-FENIL]-8-(3-TRIFLUOROMETOXI-FENIL)-2,3-DIHIDRO-BENZO[1,4]OXAZIN-4-IL]-PROPAN-2-OL, (3S,aS)-2,3-DIHIDRO-3-[3-(1,1,2,3-TETRAFLUOROETOXI)FENIL]-8-[3-(TRIFLUOROMETOXI)-FENIL]-a-(TRIFLUOROMETIL)-4H-1,4-BENZOXAZINA-4-ETANOL, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE CETP Y SON UTILES EN EL TRATAMIENTO DE ATEROSCLEROSIS, HIPER -LDL-COLESTEROLEMIA, DISLIPIDEMIA, DIABETES, OBESIDAD, ENFERMEDADES CARDIOVASCULARES Y RELACIONADAS
PE2007000570A 2006-05-11 2007-05-11 Derivados de 3,4-dihidro-2h-benzo[1,4]oxazina y tiazina como inhibidores de cetp PE20080701A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79960406P 2006-05-11 2006-05-11
US87114806P 2006-12-21 2006-12-21
US11/746,776 US7749995B2 (en) 2006-05-11 2007-05-10 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors

Publications (1)

Publication Number Publication Date
PE20080701A1 true PE20080701A1 (es) 2008-06-13

Family

ID=38694691

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000570A PE20080701A1 (es) 2006-05-11 2007-05-11 Derivados de 3,4-dihidro-2h-benzo[1,4]oxazina y tiazina como inhibidores de cetp

Country Status (8)

Country Link
US (2) US7749995B2 (es)
EP (1) EP2023934A2 (es)
JP (1) JP2009536954A (es)
AR (1) AR060904A1 (es)
CA (1) CA2651817A1 (es)
PE (1) PE20080701A1 (es)
TW (1) TW200808752A (es)
WO (1) WO2007134149A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2014034871A1 (ja) * 2012-08-30 2014-03-06 株式会社 三和化学研究所 脂質異常症の予防又は治療薬

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227506A (ja) 1985-04-01 1986-10-09 Nippon Tokushu Noyaku Seizo Kk カルバモイルイミダゾ−ル類、その中間体、それらの製法並びに除草剤又は農園芸用殺菌剤
JP3294611B2 (ja) * 1991-09-12 2002-06-24 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ４レセプター・アンタゴニスト
US5616537A (en) * 1992-07-03 1997-04-01 Kumiai Chemical Industry Co., Ltd. Condensed heterocyclic derivatives and herbicides
WO1996011920A1 (en) * 1994-10-13 1996-04-25 Pfizer Inc. Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4 (ltb4) antagonists
AU1106195A (en) 1994-11-09 1996-06-06 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
DE19638484A1 (de) * 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
DE19638486A1 (de) 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
HUP0102277A3 (en) 1998-06-09 2003-04-28 Basf Ag Herbicid composition containing a 3-heterocyclyl-substituted benzoic acid derivative preparation and use thereof
CN1158258C (zh) 1999-06-24 2004-07-21 东丽株式会社 肾上腺素能α1B受体拮抗药
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
US6583183B2 (en) * 1999-09-23 2003-06-24 Pharmacia Corporation Substituted n-phenyl-n-fused-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
WO2001057003A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
DE60128731T2 (de) * 2000-10-30 2008-02-07 Janssen Pharmaceutica N.V. Tripeptidylpeptidase-hemmer
AU2002248221B2 (en) * 2000-10-31 2006-08-17 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
ITMI20012060A1 (it) 2001-10-05 2003-04-05 Recordati Chem Pharm Nuovi eterocilcli n-acilati
CA2463686A1 (en) * 2001-10-16 2003-04-24 Dr. Reddy's Laboratories Ltd. Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them
US7015219B2 (en) * 2001-12-19 2006-03-21 Bristol-Myers Squibb Company 3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
WO2004072041A1 (en) 2003-02-12 2004-08-26 Care X S.A. Tetrahydroquinolines as agonists of liver- x receptors
WO2004072042A2 (en) 2003-02-12 2004-08-26 Carex S.A. Quinoline derivative and their use for modulation of lxr activity
WO2005096688A1 (en) 2004-04-02 2005-10-13 Original Solutions Inc. System and method for defect detection and process improvement for printed circuit board assemblies
CA2562244A1 (en) * 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds

Also Published As

Publication number Publication date
WO2007134149A3 (en) 2008-01-10
US7749995B2 (en) 2010-07-06
CA2651817A1 (en) 2007-11-22
JP2009536954A (ja) 2009-10-22
US20070265252A1 (en) 2007-11-15
TW200808752A (en) 2008-02-16
WO2007134149A2 (en) 2007-11-22
EP2023934A2 (en) 2009-02-18
US20100227857A1 (en) 2010-09-09
AR060904A1 (es) 2008-07-23
US8012963B2 (en) 2011-09-06

Similar Documents

Publication Publication Date Title
PE20080701A1 (es) Derivados de 3,4-dihidro-2h-benzo[1,4]oxazina y tiazina como inhibidores de cetp
PE20121336A1 (es) Nuevos compuestos triciclicos
PE20110906A1 (es) Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif
PE20091473A1 (es) Heterociclos como inhibidores de esteaoril-coa desaturasa
PE20080925A1 (es) DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)
PE20070367A1 (es) Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa
PE20091353A1 (es) Nuevos compuestos heterociclicos
PE20081487A1 (es) DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1
CY1115738T1 (el) Κρυσταλλικα επιδιαλυτωμενα συμπλοκα των παραγωγων (1s)-1,5-anyδpo-1-c-(3-((φainyλ)meθυλ) φαινυλ)-d-γλουσιτολης με αλκοολες οπως αναστολεις sglt2 για τη θεραπευτικη αντιμετωπιση του διαβητη
PE20120219A1 (es) Inhibidores de beta-secretasa
PE20090477A1 (es) Derivados de oxazol como inhibidores de los canales de sodio
PE20081238A1 (es) Piperidinas sustituidas como antagonistas de hdm2
PE20121474A1 (es) Nuevos compuestos de espiropiperidina
PE20091562A1 (es) Derivados de naftiridinona como inhibidores de cinasa y composiciones que los comprenden
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20070946A1 (es) COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
PE20091816A1 (es) Inhibidores de bace
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
PE20071094A1 (es) Derivados 1-ortoflurofenil sustituidos 1,2,5-tiadiazolidindionas como inhibidores de ptpasa
PE20091810A1 (es) Pirimidin-5-carboxamidas sustituidas 281
PE20081316A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
JP2009532453A5 (es)
CR9690A (es) 3-acilaminobenzanilidas insecticidas
PE20060957A1 (es) Compuestos pirazolopiridinas su preparacion y composiciones farmaceuticas
PE20080405A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
AE Restoration of lapsed or forfeited application
FG Grant, registration
FD Application declared void or lapsed